Navigation Links
Biomarker predicts malignancy potential of HG-PIN lesions in the prostate
Date:4/30/2008

PHILADELPHIA Men whose prostate cancer screenings show high grade prostatic intraepithelial neoplasia (HG-PIN) may find themselves in limbo, stuck between diagnoses they are told prostate cancer has not yet developed, but it might, and they are advised to undergo repeated needle biopsies as a precaution.

Investigators from Spain have found a means of distinguishing between HG-PIN lesions destined to become cancerous and those which will remain benign. Their findings, reported in the May 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, could spare patients the discomfort and inconvenience of unnecessary needle biopsies.

The Spanish team found that expression of the PTOV1 gene in HG-PIN lesions is linked to prostate cancer development, and that the higher the expression, the more likely it is that subsequent biopsies will find cancer. The reverse is also truelack of PTOV1 reduces the risk of prostate cancer.

This is the first HG-PIN biomarker to be associated with prostate cancer development, said the studys lead author, Rosanna Paciucci, Ph.D., a researcher at the Vall dHebrn Hospital Research Institute in Barcelona. She says that when the results of this study are validated, the PTOV1 gene marker could be used to determine which men with HG-PIN are at substantial risk of developing prostate cancer.

Those patients with a high PTOV1 score should undergo an immediate repeat biopsy, Paciucci said. On the flip side, men who test low for PTOVI may not need to receive future annoying and useless biopsies, she said. We estimate that we can save 40 percent of unnecessary biopsies - those that are repetitively negative and contain HG-PIN lesions that do not develop into cancer.

While the researchers do not know the precise biochemical function of PTOV1, they say they have found this protein promotes the proliferation of cancer cells when it is over-expressed, as it occurs in prostate cancer cells.

HG-PIN is defined as a pre-malignant lesion present in most cancerous prostates. Although a pre-malignant lesion shows many of the typical cellular changes observed in cancer, the lesion has not yet progressed fully to disease. Since HG-PIN lesions are also associated with the presence of cancer in many patients, men whose biopsies show HG-PIN are often re-biopsied until cancer is detected, Paciucci says.

In most recent studies, the average risk of cancer following a diagnosis of isolated HG-PIN in biopsy ranged from 20 percent to 30 percent, the researchers say. And while other researchers have found markers in HG-PIN lesions, none have been able to discriminate between lesions that will progress to cancer, the researchers say.

In this study, the research team analyzed HG-PIN lesions from 140 patients: the positive control group comprised 79 patients diagnosed with prostate cancer who had their prostate glands surgically removed and who had been earlier diagnosed with HG-PIN; the negative control group included 11 patients with bladder cancer who had both their diseased bladder and healthy prostate removed; and the study group comprised 50 patients diagnosed with HG-PIN but not prostate cancer. The study group had an average of 2.5 biopsies each between 2000 and 2004.

Finding that PTOV1 gene expression was elevated in HG-PIN associated with cancer, the investigators used tissue microarray and immunohistochemical analyses to see whether PTOV1 protein levels could discriminate these pre-malignant lesions from HG-PIN that did not develop into prostate cancer.

They considered both the number of cells that express the protein and the intensity of the expression, and derived a quantitative score (Hscore) that ranged from 0 to 300. From this, they calculated that an Hscore of 100 represented a highly sensitive malignancy threshold. This means that when PTOV1 Hscore is equal or above 100 the possibility to find cancer in the subsequent biopsy is 90 percent, Paciucci said. Currently, the diagnosis of cancer is made only when the cancer lesion is seen in the biopsy.

By adding the analysis of PTOV1, the positive predictive value (the chance that the HG-PIN lesion will become cancerous) of all samples, including those with a score of less than 100, is 34 percent, and the negative predictive value (the chance that the HG-PIN lesion will not become cancerous) is more than 95 percent, Paciucci says.

Paciucci cautions that the study results need to be confirmed among a larger study group. From this validation we can expect to improve the current rate of early detection of cancer, she said.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. A search for biomarkers for early detection of colorectal cancer
2. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
3. Genetic Engineering & Biotechnology News reports on cancer biomarkers
4. Biomarkers allow doctors to match therapy to patient
5. Cell response to stress signals predicts tumors in women with common pre-breast cancer
6. Built-in exercise monitor predicts fitness
7. Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity
8. How and where fat is stored predicts disease risk better than weight
9. New study predicts where corals can thrive
10. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
11. Neuronal conduction of excitation without action potentials based on ceramide production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/16/2017)...  This year,s edition of the Inc. 5000 features a now-familiar name: ... has made the list for the third year in a row. Now ... companies based on a set of quantitative metrics. In addition, BioPoint was ... in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... 2017 After spending the past two years building a ... collection, GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, ... adherence, and data collection vis a vis their members, under their ... launch of this offer. ... ...
(Date:8/15/2017)... Diego, CA (PRWEB) , ... August 15, 2017 ... ... company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch ... the number of steps needed to gain kinetic binding data for a wide ...
Breaking Biology Technology: